Sarepta (SRPT) Analysts Split on Accelerated Eteplirsen Approval - Barron's
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St slips on rising bond yields; Walmart results weigh
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Sarepta (SRPT) Trades Higher on Eteplirsen Phase II Update, Analyst Comments
November 12, 2012 11:02 AM ESTSarepta Therapeutics (Nasdaq: SRPT) is trading higher Monday following a presentations by its Chief Medical Officer (CMO) at Action Duchenne, a Duchenne muscular dystrophy (DMD) event held in London this weekend.
According to reports from theStreet.com,... More
Sarepta (SRPT) to Update on Additional Eteplirsen Phase IIb Data
October 12, 2012 4:09 PM EDTSarepta Therapeutics (NASDAQ: SRPT) announced that data from a Phase IIb study evaluating eteplirsen, an investigational treatment for boys with Duchenne muscular dystrophy (DMD), will be presented Saturday, October 13th at the World Muscle Society in Perth, Australia. Principal investigator, Jerry R. Mendell, M.D. of Nationwide Children's Hospital, will present the data in an oral presentation of the abstract titled, "Results at 48 Weeks of a Phase IIb Extension Study of the... More
Sarepta Therapeutics (SRPT) Moves Higher as Ex-FDA Official Sees Accelerated Approval
October 5, 2012 10:24 AM EDTSarepta Therapeutics, Inc. (NASDAQ: SRPT) is moving to the highs of the session and is nearly positive... More
